The only new pharmaceutical therapy for Type 2 (non-insulin-dependent) diabetes that has become available for clinical use in the last 40 years is the alpha-glucosidase inhibitor, acarbose, which reduces postprandial glucose levels by retarding digestion of complex carbohydrates in the gut. Nir Barzilai, director of the Institute for Aging Research at the Albert Einstein College of Medicine, is working on it. This strategy is facilitated by introduction of long-acting insulin glargine and biphasic insulin aspart 70/30. “Metformin continues to be an inexpensive medication and it’s very efficacious,” said the study’s lead author, Dr. Prospective Diabetes Study. Prof. The results of this trial are undermined by methodological flaws.
The medicines became popular in part because in addition to controlling blood sugar levels, they led to modest weight loss and slightly lower blood pressure. Preclinical studies indicate that incretins (GIP, GLP-1, and GLP-2) play an important role in the regulation of bone turnover. Metformin enabled normal but not T-cell–deficient SCID mice to reject solid tumors. Dr. December 2000 SmithKline Becham and Glaxo Wellcome merge to become GlaxoSmithKline (GSK) April 2001 GSK commissions the RECORD study comparing cardiovascular outcomes of Avandia to other commonly used diabetes drugs. She joined Modern Healthcare in 2014. June 2004 A legal settlement between GSK and the state of New York requires the drugmaker to post details